These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 17420189)

  • 41. Under-mined.
    Greene J
    Hosp Health Netw; 2006 Dec; 80(12):38-40, 42, 44, 1. PubMed ID: 17236454
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cerivastatin and the dissemination of adverse event information.
    Weaver SJ; Doering PL
    Ann Pharmacother; 2002 Jun; 36(6):1099-103. PubMed ID: 12058704
    [No Abstract]   [Full Text] [Related]  

  • 43. Remedies needed to address the pathology in reporting adverse reactions and Food and Drug Administration use of reports.
    Wolfe SM
    J Gen Intern Med; 2003 Jan; 18(1):72-3. PubMed ID: 12534769
    [No Abstract]   [Full Text] [Related]  

  • 44. A new analytic tool developed to assess safe use recommendations.
    Cocoros NM; Wagner A; Haynes K; Petrone AB; Fazio-Eynullayeva E; Ding Y; Izem R; Lee JY; Major JM; Nguyen M; Ju J
    Pharmacoepidemiol Drug Saf; 2019 May; 28(5):649-656. PubMed ID: 30747473
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The benefits of data mining.
    Bone A; Houck K
    Elife; 2017 Aug; 6():. PubMed ID: 28813246
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incident reporting: clarifying occurrences, incidents, and sentinel events.
    Benson-Flynn J
    Home Healthc Nurse; 2001 Nov; 19(11):701-6. PubMed ID: 12035589
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of academia and the research community in assisting the Food and Drug Administration to ensure U.S. drug safety.
    Lo Re V; Strom BL
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):818-25. PubMed ID: 17436357
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An analysis of Australian adverse drug events.
    Malpass A; Helps SC; Runciman WB
    J Qual Clin Pract; 1999 Mar; 19(1):27-30. PubMed ID: 10096721
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database.
    Mott K; Graham DJ; Toh S; Gagne JJ; Levenson M; Ma Y; Reichman ME
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1023-32. PubMed ID: 27146123
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The FDA Sentinel Initiative - An Evolving National Resource.
    Platt R; Brown JS; Robb M; McClellan M; Ball R; Nguyen MD; Sherman RE
    N Engl J Med; 2018 Nov; 379(22):2091-2093. PubMed ID: 30485777
    [No Abstract]   [Full Text] [Related]  

  • 51. More eyeballs on AERS.
    Pratt LA; Danese PN
    Nat Biotechnol; 2009 Jul; 27(7):601-2. PubMed ID: 19587659
    [No Abstract]   [Full Text] [Related]  

  • 52. Trouble at the FDA: can we fix the problems affecting you and your patients?
    Henley E
    J Fam Pract; 2006 Apr; 55(4):301-4. PubMed ID: 16608668
    [No Abstract]   [Full Text] [Related]  

  • 53. Food and Drug Administration Adverse Event Reports of Retinal Vascular Occlusions Associated With Phosphodiesterase Type 5 Inhibitor Use.
    Li AS; Pomeranz HD
    J Neuroophthalmol; 2016 Dec; 36(4):480-481. PubMed ID: 27851718
    [No Abstract]   [Full Text] [Related]  

  • 54. How to evaluate the benefit-risk profile of newly marketed drugs.
    Naldi L
    Ann Dermatol Venereol; 2010 Apr; 137(4):264-6, 261-3. PubMed ID: 20417357
    [No Abstract]   [Full Text] [Related]  

  • 55. Reported Adverse Events with Painkillers: Data Mining of the US Food and Drug Administration Adverse Events Reporting System.
    Min J; Osborne V; Kowalski A; Prosperi M
    Drug Saf; 2018 Mar; 41(3):313-320. PubMed ID: 29098610
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Medical device safety: FDA's postmarket transformation initiative.
    Schultz D
    Food Drug Law J; 2007; 62(3):593-6. PubMed ID: 17915401
    [No Abstract]   [Full Text] [Related]  

  • 57. Adverse drug events and the Freedom of Information Act: an apple in Eden.
    Stang PE; Fox JL
    Ann Pharmacother; 1992 Feb; 26(2):238-43. PubMed ID: 1554939
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adverse drug reporting issues for managers.
    Sperling RL
    Home Healthc Nurse Manag; 1999; 3(6):26-9. PubMed ID: 10876507
    [No Abstract]   [Full Text] [Related]  

  • 59. Risk management from an Asian/Pacific Rim regulatory perspective.
    McEwen J
    Drug Saf; 2004; 27(8):491-7. PubMed ID: 15154822
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MedWatch: FDA's Medical Products Reporting Program.
    Goldman SA; Kennedy DL
    Postgrad Med; 1998 Mar; 103(3):13-6. PubMed ID: 9519028
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.